ATMI, Inc. (Nasdaq:ATMI), a global technology company and a leader
in single-use process solutions, announced the signing of a
distribution agreement with Finesse Solutions, Inc., a manufacturer
of measurement and control solutions for life sciences process
applications. Over the last two years, and after several
collaborative projects, the relationship between the companies has
gained in strategic importance.
This agreement will allow both companies to offer customers
seamless support for single-use bioreactor systems enabled by the
ATMI single-use Integrity® PadReactor™ system and Finesse
SmartSystems™. The solution combines the optimized mixing and gas
transfer performance of the space-efficient PadReactor bioreactor
with the industry's leading bioreactor control platform and
single-use sensors, namely, state-of-the-art TruFluor™ sensors for
pH and dissolved oxygen and TruTorr™ sensors for pressure. The
integrated system couples the ATMI LifeScience Integrity PadReactor
bioreactor with Finesse's G3-series SmartControllers™ and TruBio®
4.X DV software, which are pre-configured for controlling process
parameters such as pH, dissolved oxygen, temperature, agitation,
gas/liquid flow and auxiliary analog inputs/loops.
The integrated ATMI-Finesse bioreactor system can be purchased
in a single transaction with follow-on application and technical
support from both ATMI and Finesse. Under the terms of the
agreement, Finesse will offer fully-integrated turnkey systems for
upstream bioprocessing. Additionally, ATMI will provide all
post-point-of-sale customer requirements for PadReactor hardware
and disposables while Finesse will support and service the
controller, sensors and software.
"Based on the DeltaV® control platform from Emerson, Finesse
controllers allow users to scale their processes seamlessly from 1
Liter lab-scale R&D bioreactors into cGMP single-use process
trains having volumes up to 2,000 Liters," stated Finesse CEO
Barbara Paldus. "By integrating our measurement and control
solutions with the PadReactor system, Finesse will be able to offer
a superior solution to its customer base for the production of
recombinant proteins or vaccines. The end results will include
suspension cell configurations as well as the most effective and
productive system for micro-carrier based processes in the
industry."
Global Director of Business Development for ATMI LifeSciences,
Jeffery Craig, added, "The PadReactor system is specifically
designed to meet the needs of cell culturists and is perfectly
suited to process development, clinical material supply and
flexible GMP manufacturing. It has an innovative, cube-shaped
bioreactor vessel which offers functionality that is comparable or
better than classical stirred-tank bioreactors. It also includes a
single-use bag integrating an internal low-shear mixing paddle and
sparger system. It is considerable end-user value that all ATMI
bags are made with our in-house produced TK8 film which is designed
specifically for cell culture and bioprocess applications."
The PadReactor system is available in sizes ranging from 25
Liter to 1,200 Liter, and has been engineered to work in harmony
with Finesse's cGMP-capable, highly configurable SmartSystems which
features comprehensive functionality combined with easy process
configuration and display.
For more information on the turnkey bioreactor system, please
contact ATMI LifeSciences or Finesse representatives. For more
information about ATMI products and services at INTERPHEX 2013,
please visit www.atmi.com/Events/interphex-2013.aspx.
About ATMI
ATMI, Inc. provides specialty semiconductor materials, and safe,
high-purity materials handling and delivery solutions designed to
increase process efficiencies for the global semiconductor, flat
panel, and life sciences industries. For more information, please
visit www.atmi.com.
About ATMI LifeSciences
ATMI LifeSciences is an acknowledged technology leader in the
field of single-use bioprocess systems and consumables for the
pharmaceutical and biopharmaceutical industries. Its innovative,
market-leading portfolio of custom-engineered, flexible packaging
solutions, single-use storage systems, mixers and bioreactors is
driving bioprocess efficiency and delivering value for
biopharmaceutical companies around the world. For more information,
please visit www.atmi-lifesciences.com.
ATMI, the ATMI logo, Integrity and PadReactor are trademarks or
registered trademarks of ATMI, Inc., in the United States, other
countries or both. All other names are trademarks of their
respective companies.
About Finesse Solutions, Inc.
California-based Finesse Solutions, Inc., has established a
proven record in providing turnkey, scalable solutions for
single-use upstream bioprocessing. The Finesse product platform
includes an extensive portfolio of novel disposable sensors,
modular configure-to-order automation hardware, and intelligent
software that can harmonize global bioprocess information and
technology transfer. Finesse also offers a complete set of services
including startup, commissioning, and validation for rapid and
reliable deployment of single-use equipment into cGMP manufacturing
applications. Visit www.finesse.com.
Finesse Solutions, the Finesse logo, SmartSystems,
SmartControllers, TruBio, TruFluor and TruTorr are trademarks or
registered trademarks of Finesse Solutions Inc., in the United
States, other countries or both. All other names are trademarks of
their respective companies.
Forward Looking Statements
Statements contained herein that relate to ATMI's future
performance, including, without limitation, statements with respect
to ATMI's anticipated results of operations or level of business
for 2013 or any other future period, are forward-looking statements
within the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on current
expectations only and are subject to certain risks, uncertainties,
and assumptions, including, but not limited to, changes in
semiconductor and life sciences industry growth (including, without
limitation, wafer starts) or ATMI's markets; competition, problems,
or delays developing, commercializing, and delivering new products;
customer-driven pricing pressure; potential loss of key customers;
problems or delays in integrating acquired operations and
businesses; uncertainty in the credit and financial markets;
ability to protect ATMI's proprietary technology; and other factors
described in ATMI's Form 10-K for the year ended December 31, 2012
and other subsequent filings with the Securities and Exchange
Commission. Such risks and uncertainties may cause actual results
to differ materially from those expressed in our forward-looking
statements. ATMI undertakes no obligation to update any
forward-looking statements.
CONTACT: ATMI Contact:
Troy Dewar
Director of Investor Relations
203.207.9349
tdewar@atmi.com
Media Contact:
Beth Willers
Impress Labs
415.846.9891
beth@impresslabs.com
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atmi Inc. (MM) (NASDAQ:ATMI)
Historical Stock Chart
From Jul 2023 to Jul 2024